The use of any first- or second-generation EGFR-TKIs alone for the treatment of intracranial involvement in patients with EGFR mutant-positive lung adenocarcinoma showed a favorable cerebral response rate of more than 50%9,10. The gene discussed is EGFR; the disease is lung adenocarcinoma.